Introduction
============

Breast cancer is the world\'s most common cancer among women and the second most common cause of cancer-related mortality in women[@B1]. Breast cancer is a highly heterogeneous disease because of its complex etiology, which includes many environmental factors and genetic alterations that cause cellular process changes; thus, breast cancer patients will show a range of clinical behaviors and different pathological entities[@B2], [@B3]. The current treatment strategies for breast cancer have adverse side effects, such as chemotherapy, which cannot distinguish between normal and cancer cells; thus, breast cancer is considered incurable, and the goal of therapy is to prolong the patient\'s survival time. There is thus an urgent need to understand the biological mechanisms underlying breast cancer and to develop novel, effective strategies for the diagnosis, treatment, and prognosis of breast cancer.

MicroRNAs (miRNAs) are a class of small noncoding RNAs of \~23 nucleotides that are thought to modulate the expression of at least 30% of all human protein-coding genes by specifically binding to the 3\'-untranslated region (3\'-UTR) of the target mRNA[@B4], [@B5]. Endogenous miRNAs exert their effects on the base-pairing of the target mRNA gene 3\'-UTR with the seed region of the miRNA (nucleotides 2-8 from its 5\' end)[@B6]. Although the number of miRNAs is small, miRNAs are powerful regulators of complex processes, such as development, cell proliferation, apoptosis, differentiation and metabolism. This is mainly due to imperfect complementary miRNAs and their target genes; each miRNA may possess \>100 targets[@B7]-[@B10]. An increasing number of studies have shown that aberrant miRNA expression participates in many diseases, including a variety of cancers[@B11], [@B12]. Breast cancer is one of these cancers, and miRNA may function as oncogenes or tumor suppressors[@B13], [@B14]. Therefore, as a key factor in signaling cascades, miRNAs are a potentially useful biomarker for clinical diagnosis and may serve as both a target and a tool in cancer therapy development[@B15].

Rap1 is a small G protein of the Ras guanosine triphosphatase (GTPase) superfamily and is important in cell motility junction formation[@B16], [@B17]. Rap1A is one of the two isoforms of Rap1 (Rap1a and Rap1b) that are expressed in mammals[@B18]. Serving as a GTPase, Rap1 acts as a molecular switch by alternating between an inactive GDP-bound and an active GTP-bound state. Previous reports have elaborated that Rap1a is involved in various essential cellular processes, such as proliferation, apoptosis, differentiation and survival[@B19]. Rap1 has been found to regulate the p38/AKT/ERK pathway to exert its effect[@B20], [@B21]. The MAPK pathway plays a critical role in many aspects of tumorigenesis and development by being involved in the regulation of cancer cell processes, such as growth, proliferation, survival, migration and apoptosis[@B22]. However, the mechanism of the Rap1a/MAPK axis in breast cancer is unclear.

In the present study, the expression of miR-433 in breast cancer was evaluated, and the potential role of miR-433 in breast cancer cell lines was investigated. Cell proliferation, migration and apoptosis were detected in miR-433 overexpression and knockdown models. In a further study, we demonstrated Rap1a to be a direct target gene of miR-433. Moreover, we evaluated the possible underlying mechanisms of Rap1a in breast cancer and tested its downstream factors.

Materials and methods
=====================

Cell lines and cultures
-----------------------

The 4T1 cells used in this study were obtained from the Chinese Academy of Sciences cell bank (Shanghai, China), and the MCF-7 and human HEK293 cells were purchased from the American Tissue Culture Collection (ATCC, Rockville, MD, USA). All cell lines were grown in RPMI 1640 medium with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C with 5% CO2.

RNA extraction and qPCR
-----------------------

Total RNA was isolated from the tissue and cell lines using TRIzol® reagent (Invitrogen, CA, USA). The total RNA was treated with DNase I and reverse transcribed into cDNA. The expression levels of miRNA were assessed using a Hairpin-it^TM^ microRNA qPCR Quantitation Kit (GenePharma, Shanghai, China) according to the standard protocol. The expression of U6 was used as an endogenous control. The total cDNA was used as the starting material for real-time PCR with FastStart Universal SYBR Green Master (Roche Applied Science, Mannheim, Germany) using the StepOne real-time PCR System (Life Technologies Corp. Waltham, MA, USA). The Primer Premier software (PREMIER Biosoft International, Palo Alto, CA, USA) was used to design specific primers for miR-433-3p, Rap1a and GAPDH based on known sequences (Table [1](#T1){ref-type="table"}). The expression levels of each target gene were normalized to the corresponding GAPDH or U6 threshold cycle (CT) values using the 2^-△△CT^ comparative method.

Transient transfection (Transfections of miRNA and small interfering RNA (siRNA))
---------------------------------------------------------------------------------

Oligonucleotide miR-433 mimics, inhibitors, Rap1a siRNA and their respective negative control oligonucleotides were purchased from GenePharma (Shanghai, China). Overexpression of Rap1a in cells was achieved via transfection with a Rap1a ORF expression clone (GeneCreate, Wuhan, China). The 4T1 and MCF-7 cells were seeded onto 6-well plates at a density of 2×10^5^ cells/ml per well. Then, the cells were washed once with prewarmed (37°C) serum-reduced Opti-MEM I medium (Invitrogen, CA, USA). The transfection of the miR-433 mimic/ inhibitor or miR-control involved 0.4 ml of Opti-MEM at a final concentration of 100 nM and 10 µg/ml Lipofectamine 2000 (Invitrogen, CA, USA) per well. The cells were incubated for 6 h at 37°C and 5% CO~2~. Subsequently, the transfection medium was replaced with complete medium containing 10% FBS.

Cell proliferation assay
------------------------

The 4T1 and MCF-7 cells were seeded on 96-well plates at a density of 6.0×10^3^ cells/well. The Cell Counting Kit-8 (CCK-8, Dojindo Laboratories, Minato-ku, Tokyo, Japan) was used to assess cell proliferation. After being transfected with miR-433 mimics, miRNA-inhibitor, and their respective negative controls for 24 h, 48 h and 72 h, the cells were continuously cultured with 10 μL of CCK-8 in each well at 37°C for 2 h. Cell proliferation was measured by absorbance (optical density) with a microplate reader (Bio-Rad Instruments, Hercules, CA, USA) at 450 nm. Each experiment was performed in triplicate.

Cell migration assay
--------------------

A wound healing assay was used to assess cell migration. As a previously described method in a study[@B23], the 4T1 and MCF-7 cells were seeded onto 6-well plates and were transfected with siRNA, miR-433 mimics, miR-433 inhibitor, and their respective negative controls, as described in the figure legends using Lipofectamine 2000. After the cells were almost covered, wounding was accomplished by dragging a 200 μL pipette tip through the monolayer. After washing the cells two times, the wound closures were photographed when the scrape wound was introduced (0 h) and at a designated time (24 and 48 h) using an inverted microscope (Olympus Corporation, CKX41, Japan). The assay was independently repeated three times.

Cell apoptosis analysis
-----------------------

The effect of miR-433 on cell apoptosis was determined using flow cytometry. Briefly, the cells were seeded onto 6-well plates overnight and transfected, and the cells were then harvested and washed twice in cold phosphate-buffered saline (PBS). Cells were stained using the Annexin-V-PI apoptosis detection kit (Becton Dickinson, Franklin Lakes, NH, USA) according to the manufacturer\'s protocol, and they were analyzed by FACS (Becton Dickinson, Franklin Lakes, NJ, USA).

Western blot analysis
---------------------

The total protein of the tissue and cells was extracted according to the manufacturer\'s recommended protocol (Vazyme, Nanjing, China). The protein concentrations were determined using the BCA protein assay kit (Vazyme, Nanjing, China). Samples with equal amounts of protein (50 μg) were fractionated on 10% SDS-polyacrylamide gels, transferred to polyvinylidene difluoride membranes and blocked with 5% skim milk in TBST for 1.5 hat 25°C. The membranes were then incubated at 4°C overnight with 1:1000 dilutions (v/v) of the primary antibodies. This study used Rap1a, a MAPK pathway sampler kit, MMP-9 antibodies purchased from Cell Signaling Technology (Beverly, MA, USA), and caspase-3, caspase-9 and PARP1 antibodies purchased from Abcam (Cambridge, UK). After washing the membranes with TBST, incubations with 1:4000 dilutions (v/v) of the secondary antibodies were conducted for 2 hrs at 25°C. Protein expression was detected using an enhanced chemiluminescence detection system. β-actin was used as a loading control.

Plasmid construction and cell transfection
------------------------------------------

To confirm the possibility of miR-433 targeting the predicted candidate gene, the 3\'-untranslated region (UTR) of Rap1a containing the miR-433 binding site was inserted into the *Xba* I and *Sac* I sites of the pGL3 promoter vector. Mutant Rap1a containing single-mutated and double-mutated base sites were constructed using a fast mutagenesis kit. The 293T cells were plated onto 6-well plates at a density of 4×10^5^ cells/ml per well and cotransfected with pGL3‑Rap1a or pGL3‑Rap1a‑MUT and miR‑433 mimics using Lipofectamine 2000.

Dual luciferase assays
----------------------

Forty-eight hours after transfection, the luciferase activity was assessed using the Dual-Glo luciferase assay kit (Promega, WI, USA), according to the manufacturer\'s protocol. In addition, luminescence intensity was read with a microplate luminometer following the manufacturer\'s protocol. The relative luciferase activity levels were determined by normalizing the levels to the activity of *Renilla* luciferase. Transfections were performed in duplicate and were repeated three times.

Immunofluorescence staining
---------------------------

After the 4T1 and MCF-7 cell lines were transfected with miR-433 mimics or si-Rap1a in 6-well-plates, the cells were collected onto slides and fixed with 4% paraformaldehyde. Immunofluorescence staining was performed. The cells were incubated with special antibody for p-p38/pERK (1:100) overnight at 4°C and then incubated with secondary antibody in the dark for 2 h at 25°C. Next, the p-p38/pERK protein was mounted using a mounting medium supplemented with 4,6-diamidino-2-phenylindole (DAPI, Beyotime, China) for nuclear counterstaining, and the protein was observed using fluorescence microscopy (Olympus, Japan).

*In vivo* experiment
--------------------

Six- to eight-week-old BALB/C female mice were purchased from the Hubei Provincial Center for Experimental Animal Research (Wuhan, China). The animal protocol was approved by the Institutional Ethical Committee for Animal Care and Use of Huazhong Agricultural University and was in line with the United States National Institutes of Health\'s published experimental animal care and use guide. All mice were fed a standard diet and were housed in a temperature-controlled room with a 12-h dark/light cycle for one week prior to the experiments. There were approximately 1.0×10^7^ 4T1 cells without any contamination that were harvested, suspended in 200 μL of PBS and then subcutaneously injected into each mouse\'s fourth breast pad. One month later, 15 mice were randomly selected, and allogeneic xenograft samples and paratumor tissue were collected.

Statistical analysis
--------------------

Data are presented as the means ± (SEM) from at least three separate experiments. Multiple group comparisons were performed with two-tailed Student\'s t-tests, and P-values \< 0.05 were considered significant.

Results
=======

The expression of miR-433 was significantly reduced in breast cancer cells and tissue
-------------------------------------------------------------------------------------

To explore the potential role of miR-433 in breast cancer, we collected 15 mammary gland homotransplants with their adjacent tissue from female Balb/c mice. To evaluate the expression of miR-433 using quantitative real-time reverse transcription-PCR (qPCR). As shown in Figure [1](#F1){ref-type="fig"}, the expression of miR-433 in breast cancer was obviously reduced.

MiR-433 affected cell viability, migration and invasion in breast cancer cells
------------------------------------------------------------------------------

To investigate the effect of miR-433 on breast cancer cell viability, invasion and migration, the miR-433 mimic and inhibitor were transfected into the 4T1 and MCF-7 cells. Transfection efficiency was validated by using RT-PCR. As shown in Figure [2](#F2){ref-type="fig"}A, the expression level of miR-433 was significantly increased in the miR-433 mimics group; however, miR-433 expression was reduced in cells transfected with the miR-433 inhibitor. The results of the cell proliferation assay indicated that compared with the control, overexpression of miR-433 significantly inhibited cell proliferation (Figure [2](#F2){ref-type="fig"}B). Similarly, the wound scraping assay indicated miR-433 inhibitor cell migration (Figure [2](#F2){ref-type="fig"}C and D). MMP-9 is a well-known matrix metalloproteinases proteinase (MMPs) that disrupts the extracellular matrix (ECM), which induces the invasion of cancer cells; thus, it has been widely studied as a major target of cancer metastasis[@B24]-[@B26]. In the present study, we assessed the ability of cells to invade by measuring the expression of MMP-9. The level of MMP-9 was clearly lower in the cells transfected with miR-433 mimics than it was in the control (Figure [2](#F2){ref-type="fig"}E and F). To conclude, miR-433 is an important element that can help inhibit breast cancer development.

Overexpression of miR-433 induces apoptosis in breast cancer cells
------------------------------------------------------------------

There is no doubt that induced apoptosis is the most effective treatment strategy for breast cancer. Therefore, using flow cytometry, we confirmed that miR-433 induced apoptosis in breast cancer cells compared with the NC group transfected with miRNA (Figure [3](#F3){ref-type="fig"}A and B). Then, expression of the apoptosis-related protein was measured by western blot, such as caspase-3, PARP1, Bax and Bcl-2 (Figure [3](#F3){ref-type="fig"}C and D). The results indicated that miR-433 increased pro-apoptosis protein expression and decreased anti-apoptosis protein expression, while the opposite occurred in the miR-433 inhibitor group. In summary, miR-433 is consistent with a tumor-suppressive function for this miRNA in 4T1 and MCF-7 cells.

Rap1a is a direct target of miR-433
-----------------------------------

To further reveal the mechanism of miR-433, we first identified the target gene of miR-433. Bioinformatic analysis is the main research method used for screening miRNA target genes, so we compared the results obtained from different searches, such as TargetScan, miRDB, and the miRanda algorithms. The results predicted Rap1a as a target of miR-433 and predicted a possible binding region of miR-433 in the 3\' untranslated region (3\'-UTR) of Rap1a (Figure [4](#F4){ref-type="fig"}A). Then, we used a dual luciferase experiment to verify the targeting effect relationship. As shown in Figure [4](#F4){ref-type="fig"}B, in the cotransfected miR-433 mimics, the PGL-3-Rap1a-3\'UTR plasmid 293T cells, the luciferase activity significantly decreased compared with the other group. However, the cotransfected PGL-3-mut-Rap1a-3\'UTR and the mimics scramble or miR-433 mimics did not affect the luciferase activity, and their luciferase activities did not display any significant differences compared with the control. In addition, the expression of Rap1a at the protein level was decreased in the transfected with miR-433 mimics cell group in 4T1 (Figure [4](#F4){ref-type="fig"}C and D). However, the expression of Rap1a at the mRNA level did not change significantly (Figure [4](#F4){ref-type="fig"}E).

The effect of knockdown Rap1a is consistent with the overexpression of miR-433
------------------------------------------------------------------------------

To elucidate the role of Rap1a in 4T1 cells, we detected the cell viability, proliferation, and apoptosis after siRNA knockdown of Rap1a. Targeting Rap1a with siRNA decreased Rap1a protein expression in 4T1 cells (Figure [5](#F5){ref-type="fig"}A and B), and significant reductions in cell proliferation, invasion and migration were observed with the transfection of siRNA against Rap1a mRNA (Figure [5](#F5){ref-type="fig"}C-G). Flow cytometric analysis and western blot assays also revealed a high proportion of apoptotic cells after transfection of Rap1a siRNA (Figure [5](#F5){ref-type="fig"}H and K). These data suggested that Rap1a is a functional target of miR-433.

Overexpression of Rap1a partially rescued the induced apoptosis effect of miRNA-433 on breast cancer cells
----------------------------------------------------------------------------------------------------------

To investigate the role of Rap1a in the miRNA-433-mediated inhibition of breast cancer cell apoptosis, 4T1 cells were transfected with miRNA-433 mimics or mimic-NC for 24 h and were subsequently transfected with Rap1a ORF clone or empty vector (pcDNA3.1(+)) for another 24 h. Western blots showed that the transfection with the Rap1a ORF clone significantly increased the Rap1a protein level compared with the control group, while cotransfection with miRNA-433 mimics + Rap1a ORF clone significantly restored the expression of Rap1a compared with the miR-433 mimic + pcDNA3.1(+) group (Figure [6](#F6){ref-type="fig"}A). As expected, we found that the overexpression of Rap1a significantly rescued the induced apoptosis effect of miRNA-433 on breast cancer cells (Figure [6](#F6){ref-type="fig"}B). Overall, these data suggested that the overexpression of Rap1a could rescue the effect of miRNA-433 induced breast cancer cell apoptosis.

The effect of miR-433 is partially dependent on the MAPK signal pathway
-----------------------------------------------------------------------

As described above, Rap1a is a direct target gene of miR-433, but the mechanism of the effect of Rap1a still needs to be studied in 4T1 cells. Previous studies have shown that Rap1a, similar to other small G proteins, can regulate multiple signaling pathways [@B27]-[@B29]. In this study, we found that miR-433 inhibits the phosphorylation of p-p38 and pERK (Figure [7](#F7){ref-type="fig"}A and B). The results of the immunofluorescence also led to the same conclusion, in which miR-433 inhibited the activation of the MAPK signaling pathway (Figure [7](#F7){ref-type="fig"}C). In addition, the results indicated the reverse in silenced Rap1a in the presence of miR-433 inhibition.

Discussion
==========

Breast cancer patients experience relapse after treatment, primarily because the traditional treatment strategies are less sensitive and specific, resulting in cancer cells being able to survive. This emphasizes the high demand for reasonable and systematic therapies. Over the past decade, miRNAs have emerged as a critical factor in various cellular processes [@B30]-[@B32]. An accumulating number of studies have indicated miRNA as salient regulators of cancer progress and have considered them novel diagnostic tools and valuable therapeutics[@B33]. Here, in this study, we demonstrated that miR-433 is downregulated in breast cancer cell lines and tissue using qRT-PCR. Then, we conjectured that miR-433 exerts an important effect on the development of breast cancer. To confirm this hypothesis, we established miR-433 overexpression and knockdown models in breast cancer cell lines. In a further study, we indicated that overexpression of miR-433 significantly attenuated breast cancer cell migration and proliferation and that this overexpression induced apoptosis.

The miRNAs are divided into two main types in cancer: oncogenes and tumor suppressor genes, and miRNAs have been shown to be differentially expressed in different types of cancer, meaning that one miRNA has different functions in different tissues. Previous studies mostly defined miR-433 as an oncogene. As in ovarian cancer, miR-433 induced cellular senescence by disrupting cell cycle progression[@B34]. In gastric cancer cells, miR-433 targets KRAS to inhibit cell migration and proliferation *in vitro*[@B35]. In colorectal cancer, the upregulation of miR-433 was able to reduce viability and promote apoptosis by downregulating MACC1[@B36]. In hepatocellular carcinoma, miR-433 is a potent inhibitor of HCC cell proliferation by targeting PAK4[@B15], GRB2 and HDAC6[@B37]. However, the mechanism of miR-433 in breast cancer remains unclear. In this study, we demonstrated that the aberrant expression of miR-433 is involved in the progression of breast cancer. Because one miRNA can control multiple genes by binding to the 3′-UTRs of target mRNAs, the combined biological effects are largely influenced by the specific genetic background of the types of cells or tumors in which the miRNA is expressed[@B38]. Thus, the seemingly distinct functions of miR-433 in different types of cancer reflect the intrinsic complexities and diversities of tumor biology. In this study, we found that the miR-433 expression levels were significantly reduced in breast cancer and that the overexpression of miR-433 inhibited cell proliferation and migration and induced apoptosis.

To further investigate the mechanism of miR-433 in breast cancer, we searched for miR-433 potential target genes using a variety of bioinformatic methods. The genes that were predicted by all the algorithm programs we used (TargetScan, miRDB and miRanda) were selected as the candidate targets. The candidate target gene Rap1a was confirmed as a direct target of miR-433 using dual fluorescein reporter assays. Rap1a, a member of the RAS oncogene family, has been shown to demonstrate aberrant expression in multiple malignant tumors[@B39]. As mentioned before, Rap1a has been implicated in the processes of cell division, proliferation, apoptosis and differentiation. However, a previous study suggested the efficacy of Rap1a in cell and/or environment-specific contexts[@B40]. Recent evidence suggested that knocking down Rap1a can sensitize cancer cells to chemotherapy and then regulate the prognoses of cancer patients, such as in lung cancer[@B41]. In prostate cancer, activation of Rap1 promotes metastasis[@B42]. There is a consensus from studies of several kinds of cancer that the over-activation of Rap1 induces cancer cell proliferation and tumorigenesis[@B43], [@B44]. In the present study, we found that knockdown of Rap1a inhibited cell proliferation and invasion and induced apoptosis, and overexpression of Rap1a partially rescued the induced apoptosis effect of miRNA-433 on breast cancer cells. These findings all indicated that Rap1a is a functional target of miR-433, and this evidence suggested that miR-433 exerts its tumor-suppressive effects through the downregulation of Rap1a in breast cancer cells.

In addition, we noted that miR-433 overexpression decreased the levels of proteins related to the MAPK pathway, and this function of miR-433 could act directly or indirectly through this pathway. A further study showed that Rap1a silencing could phenocopy the regulatory effects of miR-433 on the MAPK pathway. Interestingly, since Rap1 was first identified, the relationship between the ras/ERK signaling and the effect of Rap1 on cell proliferation has been closely examined[@B45]. Currently, Rap1 is thought to participate in many cellular processes by mediating the MAPK pathway, which has been demonstrated in a variety of cell types[@B46]-[@B48]. The results of the present study indicated that miR-433 silences Rap1a, thereby inhibiting the MAPK signaling pathway, in its role as a tumor suppressor gene.

Briefly, we identified miR-433 as a tumor suppressor gene in breast cancer and Rap1a as a novel functional target of miR-433. The functions of miR-433 include suppressing cell proliferation, migration and invasion and inducing apoptosis via inactivation of the MAPK signaling pathway. All of these data revealed a novel tumor-suppressing mechanism in breast cancer, indicating that miR-433 may serve as a diagnostic and potential therapeutic target in breast cancer patients.
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![**Expression of miR-433 in breast cancer specimens.** Comparison of miR-433 expression in 15 paired tumor and adjacent non-tumor tissues using qRT-PCR. These specimens were collected in homotransplants from Balb/c female mice. The experiments were performed three times. Data are presented as the mean ± S.E.M. The symbol \*\* denotes a significant difference of P\< 0.01.](ijbsv14p0622g001){#F1}

![**High expression of mir-433 inhibited cell proliferation, migration and invasion. A.** The expression levels of miR‑433 in 4T1 and MCF-7 cells transfected with mimics-NC, miR-433 mimics, inhibitor-NC and miR-433 inhibitor were detected using reverse transcription-quantitative polymerase chain reactions. **B.** CCK-8 were used to assess the proliferation of 4T1 and MCF-7 cells transfected with oligonucleotides at 0 h, 24 h, 48 h and 72 h. **C, D.** Wound healing assays of 4T1 and MCF-7 cells after transfection with miR-NC, miR-433 mimics, inhibitor-NC and miR-433 inhibitor. Representative images depicting the beginning (t = 0 h) and the end (t = 24 h) of the recording period are shown. **E, F.** The protein expression levels of MMP-9 were detected using western blots. β-actin was used as the control. All results are expressed as the mean ± S.E.M. of three independent experiments. The symbols \* and \*\* denote significant differences of P\<0.05 and P\< 0.01, respectively.](ijbsv14p0622g002){#F2}

![**Overexpression of miR-433 induced apoptosis in 4T1 and MCF-7 cells. A, B.** Cell apoptosis assays of 4T1 and MCF-7 cells treated with NC, miR-433 mimics, inhibitor-NC or miR-433 inhibitor using FACS. Cells were collected and labeled with Annexin V-FITC and PI. **C, D.** Western blot analyses of caspase-3, Bax, Bcl-2 and PARP1 treated with NC, miR-433 mimics, inhibitor-NC or miR-433 inhibitor. β-actin was used as an internal control. All results are expressed as the mean± S.E.M. of three independent experiments. The symbols \* and \*\* denote significant differences of P\<0.05 and P\< 0.01, respectively.](ijbsv14p0622g003){#F3}

![**Rap1a is a gene target of miR-433. A.** Schematic of predicted miR-433 binding sites in the Rap1a-3′UTR. **B.** The pmirGLO-3 reported plasmids, those containing the 3\'-UTRs of the wild-type Rap1a mRNA or those with a 3\'-UTR with mutated miR-433-binding sites were cotransfected along with miR-433 mimics or mimics-NC into HEK293T cells, after 24 h of which, the luciferase activity was measured using the dual luciferase reporter assay system. **C, D.** The protein expression levels of Rap1a in the 4T1 cells transfected with miR-433 mimics were determined using western blot. β-actin was used as an internal control. **E.** The mRNA expression levels of Rap1a were detected in 4T1 cells transfected with miR-433 using qRT-PCR. All results are expressed as the mean± S.E.M. of three independent experiments. The symbol \*\* denotes a significant difference of P\< 0.01.](ijbsv14p0622g004){#F4}

![**Rap1a is a functional target of miR-433. A, B.** The protein expression levels of Rap1a in si-Rap1a transfected 4T1 cells were determined using Western blot. β-actin was used as an internal control. **C.** CCK-8 were used to assess the proliferation of 4T1 cells transfected with si-Rap1a at 0 h, 24 h, 48 h and 72 h. **D, E.** Wound healing assays of 4T1 cells after transfection with si-Rap1a. Representative images depicting the beginning (t = 0 h) and the end (t = 24 h) of the recording period are shown. **F, G.** The protein expression levels of MMP-9 were detected using western blot. **H, I.** Cell apoptosis assays of 4T1 cells treated with si-Rap1a using FACS. **J, K.** Western blot analyses of caspase-3, Bax, Bcl-2 and PARP1 treated with si-Rap1a. β-actin was used as an internal control. All results are expressed as the mean ± S.E.M. of three independent experiments. The symbols \*\* and \*\*\* denote significant differences of P\<0.01 and P\< 0.001, respectively.](ijbsv14p0622g005){#F5}

![**overexpression Rap1a can reverse the effect of miR-433 induced apoptosis. A, B.** The protein expression level of Rap1a in Rap1a ORF clone transfected 4T1 cells were determined using Western blot. β-actin was used as an internal control. **C, D.** Cell apoptosis assays of 4T1 cells treated with Rap1a ORF cDNA clone expression plasmid using FACS. All results are expressed as the mean ± S.E.M. of three independent experiments. The symbols \*\* denote significant differences of P\< 0.01.](ijbsv14p0622g006){#F6}

![**The effect of miR-433 on 4T1 cells was exerted through regulation of the MAPK signal pathway. A, B.** After 4T1 cells were transfected with miR-433 mimics, si-Rap1a and the corresponding controls, the protein expression levels of p38, p-p38, ERK and pERK were detected by western blot. β-actin was used as an internal control. **C.** Immunofluorescence images showing transfection with miR-433 mimics or si-Rap1a inhibits p-p38 and pERK activation in 4T1 cells. All of the data represent the mean ± S.E.M. of three independent experiments. The symbol \*\* denotes a significant difference of P\< 0.01.](ijbsv14p0622g007){#F7}

###### 

Primer sequence for qPCR

  Gene                              Primer sequence(5\'-3\')                                 product size(bp)
  --------------------------------- -------------------------------------------------------- ------------------
  Rap1a                             Forward:CAAGCTAGTAGTCCTTGGTTCAG                          106
  Reverse:GGAATCTTCTATCGTTGGGTCAT                                                            
  GAPDH                             Forward:AACAGCAACTCCCACTCTTC                             111
  Reverse:CCTGTTGCTGTAGCCGTATT                                                               
  miR-433                           Stem-loop:CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGacaccgag   
  Forward:TCGGCAATCATGATGGGCTCCTC                                                            
  Reverse:CTCAACTGGTGTCGTGGAGTC                                                              
  U6                                Stem-loop:CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGcaatcagc   
  Forward:CTCGCTTCGGCAGCACA                                                                  
  Reverse:AACGCTTCACGAATTTGCGT                                                               
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